Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00268918
Other study ID # 05-020
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2005
Est. completion date January 2011

Study information

Verified date July 2018
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to see if the study drug, PTK787, is safe and to find the highest dose that can be given safely without causing serious side effects.


Description:

- Patients will come to the clinic once a week to receive study treatment. To help reduce the chance of an allergic reaction patients will take Decadron tablets orally the night before, the morning of and the evening of receiving chemotherapy.

- The lead-in schedule of dosing is as follows: Day 1: Taxotere intravenously; Day 4: PTK787 orally; Day 14: Taxotere and PTK787.

- After the lead-in schedule, a cycle will consist of 28 days. PTK787 will be given orally once a day without interruption. Taxotere will be given on Day 1, Day 8, Day 15 and Day 22.

- Before each dose of Taxotere, blood tests, urine tests, and a physical exam will be done. A radiological evaluation will be done every two months. If the patients tumor remains stable or shrinks in size, they may continue to stay on the study.

- Patients should not eat grapefruit or drink grapefruit juice during this study.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date January 2011
Est. primary completion date January 2007
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Recurrent gynecological cancers or metastatic breast cancer. Initial diagnosis must be confirmed histologically.

- Measurable disease or nonmeasurable disease

- Age > 18 years

- ECOG performance 0,1,2

- 4 weeks or greater since major surgery, 3 weeks or greater since chemotherapy

- Certain lab values

- Negative for proteinuria

Exclusion Criteria:

- Four or more treatment regimens

- History or presence of uncontrolled CNS disease

- Prior biologic or immunotherapies less than 3 weeks prior to registration

- Prior full field radiotherapy less than 4 weeks or limited field radiotherapy less than 2 weeks prior to registration

- Prior therapy with anti-VEGF agents

- Peripheral neuropathy with functional impairment > CTC grade 2

- Pregnant or breast feeding

- Concurrent severe and/or uncontrolled medical condition

- Chronic renal disease

- Acute or chronic liver disease

- Impairment of gastrointestinal function or GI disease

- Confirmed diagnosis of HIV infection are excluded at the investigators discretion

- Therapeutic warfarin sodium or similar oral anticoagulants that are metabolized by the cytochrome p450 system.

Study Design


Intervention

Drug:
Docetaxel
Participants may continue receiving study drug as long as their disease does not worsen
PTK787
Participants may continue receiving study drug as long as their disease does not worsen

Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (3)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute Brigham and Women's Hospital, Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the maximum tolerated dose and the dose limiting toxicity of weekly Taxotere patients treated with PTK787. 2 years
Secondary To estimate the preliminary efficacy of this combination in both metastatic breast cancer patients and refractory gynecological patients. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A